A detailed history of Bi Asset Management Fondsmaeglerselskab A transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Bi Asset Management Fondsmaeglerselskab A holds 4,562 shares of ALNY stock, worth $1.23 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
4,562
Previous 3,724 22.5%
Holding current value
$1.23 Million
Previous $557,000 99.1%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$143.31 - $247.0 $120,093 - $206,986
838 Added 22.5%
4,562 $1.11 Million
Q1 2024

May 03, 2024

SELL
$146.51 - $198.2 $6,592 - $8,919
-45 Reduced 1.19%
3,724 $557,000
Q4 2023

Feb 09, 2024

BUY
$151.41 - $196.57 $314,327 - $408,079
2,076 Added 122.62%
3,769 $721,000
Q3 2023

Nov 13, 2023

SELL
$170.77 - $211.65 $88,117 - $109,211
-516 Reduced 23.36%
1,693 $300,000
Q2 2023

Aug 03, 2023

SELL
$185.01 - $212.05 $1.82 Million - $2.09 Million
-9,853 Reduced 81.69%
2,209 $420,000
Q1 2023

May 12, 2023

BUY
$182.66 - $235.53 $1.17 Million - $1.51 Million
6,432 Added 114.25%
12,062 $2.42 Million
Q4 2022

Feb 13, 2023

BUY
$185.53 - $241.31 $504,827 - $656,604
2,721 Added 93.54%
5,630 $1.34 Million
Q3 2022

Nov 07, 2022

SELL
$138.54 - $232.0 $30,617 - $51,272
-221 Reduced 7.06%
2,909 $582,000
Q2 2022

Aug 12, 2022

BUY
$120.42 - $169.29 $151,970 - $213,643
1,262 Added 67.56%
3,130 $457,000
Q1 2022

May 11, 2022

BUY
$127.18 - $173.91 $237,572 - $324,863
1,868 New
1,868 $305,000
Q4 2020

Feb 12, 2021

SELL
$122.97 - $147.0 $36,030 - $43,071
-293 Closed
0 $0
Q3 2020

Nov 09, 2020

BUY
$121.19 - $165.49 $35,508 - $48,488
293 New
293 $43,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $33.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Bi Asset Management Fondsmaeglerselskab A Portfolio

Follow Bi Asset Management Fondsmaeglerselskab A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

News

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.